Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Sep;9(9):2812-2818.
doi: 10.21037/jtd.2017.08.79.

Moving more potent and less toxic options to the frontline in the management of advanced lung cancer

Xiuning Le  1 , Deepa Rangachari  1 , Daniel B Costa  1
Affiliations
Editorial

Moving more potent and less toxic options to the frontline in the management of advanced lung cancer

Xiuning Le et al. J Thorac Dis. 2017 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: DB Costa has received consulting fees and honoraria from Pfizer, Boehringer Ingelheim and Ariad pharmaceuticals; outside the submitted work. Other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Schema of management of advanced non-small-cell lung cancer (NSCLC) based on histology, tumor biomarkers and line of therapy. EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; ROS1, ROS proto-oncogene 1; TPS, tumor proportion score; PD-1, programmed cell death 1; PD-L1, programmed death-ligand 1; IHC, immunohistochemistry.
Figure 2
Figure 2
Management of advanced ALK rearranged lung cancer before and after the J-ALEX, ALEX and ASCEND-4 trials. *, for countries and areas that alectinib is not approved or available, crizotinib or ceritinib are still the recommended first line treatment.
See this image and copyright information in PMC

Comment on

References

    1. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150:1107-20. 10.1016/j.cell.2012.08.029 - DOI - PMC - PubMed
    1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. 10.1056/NEJMoa040938 - DOI - PubMed
    1. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. 10.1126/science.1099314 - DOI - PubMed
    1. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11. 10.1073/pnas.0405220101 - DOI - PMC - PubMed
    1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. 10.1038/nature05945 - DOI - PubMed

LinkOut - more resources